Physician profile
Christopher A Smith
NPI 1811911944
$1,466.32
in general payments reported to CMS, 2019-2025
22 companies · $434 in 2025
The $434 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $206 · 2023: $412 · 2024: $414 · 2025: $434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,260.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $347.35 | 2022-2025 | Ozempic, Rybelsus, Tresiba |
| Abbvie INC. | $259.99 | 2023-2025 | Vraylar, Qulipta, Ubrelvy |
| Abbott Laboratories | $95.70 | 2023-2024 | Freestyle Libre 3 |
| Astellas Pharma US INC | $93.38 | 2022-2024 | Veozah, Myrbetriq |
| Lilly USA, LLC | $76.27 | 2022-2024 | Mounjaro, Zepbound |
| Pfizer INC. | $67.41 | 2024-2025 | |
| Amgen INC. | $64.48 | 2022-2025 | Krystexxa |
| Janssen Pharmaceuticals, INC | $62.55 | 2022-2023 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $60.32 | 2025 | Caplyta |
| Dexcom, INC. | $57.62 | 2022-2023 | Dexcom G6 Transmitter |
| Inari Medical, INC. | $49.50 | 2023-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Novartis Pharmaceuticals Corporation | $38.14 | 2023 | |
| Antares Pharma, INC. | $37.95 | 2023-2025 | Xyosted, Nocdurna, Tlando |
| Xeris Pharmaceuticals, INC. | $22.61 | 2022 | |
| Medtronic, INC. | $19.49 | 2024 | Intellis Adaptivestim |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $18.90 | 2023 | Shingrix |
| Biohaven Pharmaceutical Holding Company LTD. | $18.85 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.18 | 2023 | Xifaxan |
| Ascensia Diabetes Care US INC. | $17.10 | 2023 | |
| Inspire Medical Systems, INC. | $16.70 | 2025 | Inspire |
| Shield Therapeutics INC | $15.88 | 2025 | |
| Dynavax Technologies Corporation | $7.95 | 2023 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.